Ariad Pharmaceuticals (NASDAQ:ARIA) is one of today's biggest movers, down 2.1% to $14.55. The Dow is down 0.4% to 12,609 and the S&P is currently trading fractionally lower to 1,311.
In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $5.52 and a high of $15.34 and are now at $14.55, 164% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 1.0% while the 50-day MA has advanced 1.9%.
ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.
Ariad Pharmaceuticals has overhead space with shares priced $14.55, or 18.7% below the average consensus analyst price target of $17.90. The stock should discover initial support at its 50-day moving average (MA) of $12.42 and subsequent support at its 200-day MA of $10.57.
